NTLA - Intellia Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
13.99
+0.10 (+0.72%)
At close: 4:00PM EST

13.99 0.00 (0.00%)
After hours: 4:48PM EST

Stock chart is not supported by your current browser
Previous Close13.89
Open13.97
Bid13.00 x 1400
Ask14.18 x 900
Day's Range13.66 - 14.01
52 Week Range11.03 - 35.99
Volume458,162
Avg. Volume583,143
Market Cap607.436M
Beta (3Y Monthly)2.91
PE Ratio (TTM)N/A
EPS (TTM)-2.16
Earnings DateAug 3, 2017 - Aug 7, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est39.79
Trade prices are not sourced from all markets
  • GlobeNewswire9 days ago

    Research Report Identifies Norfolk Southern, DENTSPLY SIRONA, Healthcare Realty Trust, PTC, Intellia Therapeutics, and El Paso Electric with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Feb. 06, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • German firm that serves gene therapy biotechs opens Cambridge HQ
    American City Business Journals14 days ago

    German firm that serves gene therapy biotechs opens Cambridge HQ

    Ahead of the opening this week, the German biotech firm signed two major partnerships with Boston-based Orchard Therapeutics and San Francisco-based Denali Therapeutics, and is also in the process of closing another partnership with a U.S. biotech company focused on hemophilia treatments.

  • 3 Biotech Stocks That Are Set for a Breakthrough
    InvestorPlace14 days ago

    3 Biotech Stocks That Are Set for a Breakthrough

    The future of medicine is all about the personalization of medicine. That means doctors will be able to tailor treatments that fit your specific ailments. Not the general ailments of a large population of people. Today, medicine is designed to treat the most common symptoms of a disease. So everyone with that same disease will be given the exact same treatment. But considering we all have different genetic makeups, this method is clearly not ideal. That is where gene editing -- the ability to edit a human's genome -- comes into play. InvestorPlace - Stock Market News, Stock Advice & Trading Tips The term "gene editing" oftentimes has a negative connotation. And given some of the post-apocalyptic movies that have become popular over the years, I can understand why some people are afraid. But genetic editing has so much to offer to the future of medicine. A couple of months ago, a Chinese scientist performed the first gene edit on a human by removing the gene that causes HIV in several newborns. The scientific community was not happy as most believe the science is not far enough along to verify its safety. However, the scientist proved that gene editing does have a place in the healthcare of tomorrow. There are currently more than 10,000 known monogenic diseases that do not have a cure. A monogenic disease is caused by the mutation of one gene. Yes, one single gene. Imagine being able to repair that gene and cure a disease immediately. That's exactly what science is working toward. Sickle cell disease is one of the terrible ailments that falls into this category. Today, those with this disease live with ongoing pain and the knowledge that their life will likely be shortened. But soon, science will be able to cure these people with a single procedure. * 10 Cold Weather Stocks to Heat Up Your Returns Imagine the diseases that could be irradiated through the practice of gene editing. There are many companies working toward this goal, and today I'd like to introduce you to three of the major biotech stocks to buy that focus on gene editing. Source: Shutterstock ### Crispr Therapeutics (CRSP) Crispr Therapeutics AG (NASDAQ:CRSP) is the largest of the Big Three gene-editing biotech stocks, and it has a slight lead in the race. The company made headlines in October when the Food and Drug Administration removed its clinical hold on CTX001, Crispr's gene therapy to treat sickle cell disease. Then, on Jan. 4, the FDA granted the therapy Fast Track status. This is extremely important because it allows for more frequent interaction with the FDA review team as well as a rolling review of the marketing application. Crispr Therapeutics is backed by some powerful pharma partners. Combine that with the promising treatments making headway in the United States and Europe and it is clear that this company is a great place to start investing in this innovative and inspiring trend that should make investors a lot of money. Source: Shutterstock ### Editas Medicine (EDIT) Editas Medicine (NASDAQ:EDIT) falls in the middle of the Big Three gene-editing biotech stocks to buy. It can trace its roots back to the biggest players in the industry, specifically Feng Zhang, whose affiliation with the Broad Institute has given Editas a significant leg up. The Broad Institute owns the patents to use Crispr technology in eukaryotic cells -- more complex cells that have a nucleus where the genetic material is found -- so it puts Editas in an enviable position since it has the exclusive rights to the patents for any genetic target it chooses. * 10 High-Yield Monthly Dividend Stocks This company's promising pipeline and connections make me confident that it is one of the key stocks to buy for investors interested in profiting from gene editing over the long term. Source: Pixelbay (Modified) ### Intellia (NTLA) Intellia Therapeutics (NASDAQ:NTLA) doesn't get the same amount of press as its fellow gene-editing stocks. It is also the smallest of the three, but its upside is just as huge as the other stocks to buy on this list. I say that because Intellia stands out thanks to its proprietary lipid nanoparticle delivery (LNP) technology. This takes drug therapies directly to the genes that need to be edited and does it right there rather than having to extract the gene edit it in the lab. The process has proven to be safer and more effective than the alternatives. Intellia has many irons in the fire as well as collaborations with two successful pharmaceutical companies, and I suspect it could have several therapies in FDA trials in the coming years. The key for gene-editing stocks to buy like NTLA will be to continue their partnerships and show progress, and that's exactly what it is doing. Source: Shutterstock ### Breakthrough Stocks I want to make one final note … gene-editing stocks are what I call buried treasure stocks … you could also call them breakthrough stocks since they're under the biotech frame. That means that the big returns I believe are possible take patience and time. Most investors don't have the long-term outlook that this kind of world-changing technology requires. * The 7 Best Penny Stocks to Buy If that's you, here is my suggestion: Go out and dig a big hole in your backyard. Bury these breakthrough stocks in it, and in 10 years you can dig up your buried treasure. Metaphorically speaking, of course. Matthew McCall is the founder and president of Penn Financial Group, an investment advisory firm, as well as the editor of Investment Opportunities and Early Stage Investor. He has dedicated his career to getting investors into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA), +1,044% in Tesla (TSLA), +611% in Liquefied Natural Gas Limited (LNGLY), +324% in Bitcoin Services (BTSC), just to name a few. If you're interested in making triple-digit gains from the world's biggest investment trends BEFORE anyone else, click here to learn more about Matt McCall and his investments strategy today. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 of the Best Stocks to Buy for a Dovish Federal Reserve * 5 Best Fidelity ETFs for Retirement Savers * 7 Blue-Chip Stocks That Could Lead the Market Higher Compare Brokers The post 3 Biotech Stocks That Are Set for a Breakthrough appeared first on InvestorPlace.

  • GlobeNewswire22 days ago

    Intellia Therapeutics Names Fred Cohen, M.D., to Board of Directors

    Intellia Therapeutics, Inc. (NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, has appointed Fred Cohen, M.D., D.Phil, F.A.C.P., to its board of directors. “We are honored to have Fred join Intellia’s board of directors.

  • Editas CEO Resigns — Sending All 3 CRISPR Stocks Into Free Fall
    Investor's Business Daily24 days ago

    Editas CEO Resigns — Sending All 3 CRISPR Stocks Into Free Fall

    Editas Medicine stock collapsed Tuesday — sending gene-editing stocks Crispr and Intellia also crashing — after Chief Executive Katrine Bosley said she will resign March 1.

  • Here's Why Intellia Therapeutics Stock Lost 23.8% in December
    Motley Foollast month

    Here's Why Intellia Therapeutics Stock Lost 23.8% in December

    The gene-editing pioneer was an easy target during the end-of-the-year market sell-off.

  • The Best CRISPR Stock Gained 21% in 2018, While The Worst Lost 29%
    Motley Foollast month

    The Best CRISPR Stock Gained 21% in 2018, While The Worst Lost 29%

    The three gene-editing pioneers had mixed results last year, but each has big plans for the year ahead.

  • Vertex, CRISPR's Sickle Disease Drug Gets FDA's Fast Track Tag
    Zackslast month

    Vertex, CRISPR's Sickle Disease Drug Gets FDA's Fast Track Tag

    FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for the treatment of sickle cell disease.

  • These Stocks Pop After FDA Expedites Review Of Gene-Editing Therapy
    Investor's Business Dailylast month

    These Stocks Pop After FDA Expedites Review Of Gene-Editing Therapy

    Crispr Therapeutics popped Friday after the FDA said it would expedite review of its Vertex Pharmaceuticals-partnered gene-editing sickle cell disease treatment.

  • InvestorPlace2 months ago

    Why CRSP Stock Has Added Layers of Risk

    Biotech stocks like CRISPR Therapeutics (NASDAQ:CRSP) are inherently risky, and inherently volatile. CRISPR stock itself, only public for a little over two years, is a good example. CRSP stock went public at $14 — and cleared $70 this year.

  • This Biotech Stock Could Launch Its First CRISPR Drug In 2022
    Investor's Business Daily3 months ago

    This Biotech Stock Could Launch Its First CRISPR Drug In 2022

    Crispr Therapeutics will launch a gene-editing therapy in the U.S. in 2022, an analyst predicted Friday as he initiated coverage with a buy rating.

  • Why Crispr Therapeutics Stock Is Up By 65% So Far in 2018
    Motley Fool3 months ago

    Why Crispr Therapeutics Stock Is Up By 65% So Far in 2018

    The gene-editing specialist has been a rare bright spot within the hard hit biotech space this year. Here's why.

  • Zacks3 months ago

    The Market is All Packed for Buenos Aires

    The Market is All Packed for Buenos Aires

  • Benzinga3 months ago

    Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns'

    With more and more genetic medicine companies going commercial, Leerink turned its attention to the sector this week.  The Analyst Leerink’s Mani Foroohar initiated coverage of 10 genetic medicine companies ...

  • With genetically edited babies, a scientist transgresses a moral boundary
    MarketWatch3 months ago

    With genetically edited babies, a scientist transgresses a moral boundary

    A Chinese scientist from a university in Shenzhen claims he has succeeded in creating the world’s first genetically edited babies. We have no idea what effects the alteration of genes in sperm or ova or a fetus will have on future generations. CRISPRs evolved over millions of years to trim pieces of genetic information from one genome and insert it into another.

  • Mass. biotech leaders voice alarm over report of first gene-edited babies
    American City Business Journals3 months ago

    Mass. biotech leaders voice alarm over report of first gene-edited babies

    The researcher's claims, which have not yet been published in a scientific paper, prompted a swift outcry among Boston-area life sciences officials Monday, given that such genetic changes can be passed on to future generations.

  • A Financial Overview of CRISPR Therapeutics in November
    Market Realist3 months ago

    A Financial Overview of CRISPR Therapeutics in November

    CRISPR Therapeutics (CRSP) reported revenues of $563,000 in the third quarter—compared to $2.4 million in the third quarter of 2017. CRISPR Therapeutics reported net revenues of $3.0 million over the first nine months of 2018—compared to $8.7 million during the same period in 2017. CRISPR Therapeutics’ net revenues are mainly from collaborations undertaken by the company.

  • CRISPR Therapeutics: Analysts’ View in November
    Market Realist3 months ago

    CRISPR Therapeutics: Analysts’ View in November

    On November 9, CRISPR Therapeutics’ (CRSP) stock price closed at $36.37, which is an ~3.53% decline from its close of $37.70 on November 8. On November 7, after the company reported its third-quarter financial results, the stock price grew ~10.81% to $38.85 from the close of $35.06 on November 6.

  • Cambridge's Editas asks FDA to start gene editing trial
    American City Business Journals3 months ago

    Cambridge's Editas asks FDA to start gene editing trial

    Editas Medicine could be the next to test the widely watched gene editing technology CRISPR/Cas9 after filing a clinical trial application late last month, the company revealed Wednesday.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of NTLA earnings conference call or presentation 31-Oct-18 12:00pm GMT

    Q3 2018 Intellia Therapeutics Inc Earnings Call

  • Here's Why CRISPR Stocks Fell as Much as 40.7% in October
    Motley Fool3 months ago

    Here's Why CRISPR Stocks Fell as Much as 40.7% in October

    It was a busy month for gene editing stocks, which suffered from both CRISPR-specific news and the broader stock market's fall.